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A randomised clinical trial on the effectiveness of topical non-steroidal anti 
inflammatory drug for painful temporomandibular disorders 
 
Aim: The aim of this study was to determine whether a topical non-steroidal  
anti-inflammatory drug (NSAID) is more effective than placebo for the treatment of 
painful temporomandibular disorders. 
  
Methods: Forty eight patients (28 females and 20 males) clinically diagnosed with a 
painful temporomandibular disorder were recruited. Each subject underwent an initial 
assessment and was then randomly assigned a topical NSAID (Diclofenac 1g/100g) or 
a placebo. The subjects were reassessed after a two-week period. The primary 
outcome measure was the change in pain as assessed with an 11-point numerical 
rating scale. A number of secondary outcomes were also assessed. 
 
Results: The median change in the 11-point numerical pain rating scale in the active 
group was -1 whilst the placebo group was 0. However, this was not statistically 
significant, (p>0.05).  
 
Discussion and Conclusions: Notwithstanding the limitations of this study including 
the limited sample size and narrow subject selection, the study suggests that the use of 
NSAIDs for the treatment of temporomandibular disorders does not provide better 
results when compared to a non-active topical cream.   
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Introduction 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used 
medications1. The physiological effect is caused by the reduction of prostaglandin 
production which sensitises nerve endings at the site of injury. This occurs primarily 
due to the inhibition of the cyclooxygenase (COX) enzyme that converts arachidonic 
acid liberated from the phospholipid membrane. There are two forms of COX which 
exist, COX-1 which is found in the stomach and kidneys and has a physiological role 
in maintaining tissue integrity. The second form, COX-2, is induced by inflammatory 
mediators and has a significant role in pain and inflammation. The development of 
selective COX-2 inhibitors has been a major development in drug therapy. This has 
enabled the reduction of adverse side effects associated with NSAIDs. This strategy 
targets the production of prostaglandins specifically involved in pain and 
inflammation while sparing prostaglandins that exert important physiological roles 
such as maintaining the integrity of the gastric lining and normal renal function1. 
Nevertheless these drugs have been associated with some adverse events including  
nausea, vomiting, diarrhoea, constipation, decreased appetite, rash, dizziness, 
headache and drowsiness. The most serious side effects include kidney failure, liver 
failure, ulcers and prolonged bleeding.  
 
The development of topical formulations of NSAIDs has been an additional strategy 
to minimise the adverse effects of NSAIDs. This delivery route can minimise plasma 
concentrations of drugs and lead to fewer side effects2. Bioavailability and plasma 
concentrations following topical application are 5 to 15% of those achieved by 
systemic delivery2. When NSAIDs are administered topically, relatively high 
concentrations occur in the dermis, whereas levels in the muscle are at least 
equivalent to those following systemic administration2.   
 
The currently accepted pharmacological treatment approaches for temporomandibular 
disorder (TMD) pain have not been subjected to rigorous scientific examination. This 
is particularly true in the case of NSAIDS which are used extensively in the treatment 
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of mild to moderate musculoskeletal pain and are recommended as a first line drug for 
treatment of TMDs3,4. A meta-analysis of TMD management5 consisting of  more 
than 4000 references which were identified between 1980 and 1992 was published in 
1995. Only 1% (n = 50) were randomised controlled trials. Of these, 5 were drug 
studies, providing an extremely small pool of evidence upon which to base 
recommendations regarding efficacy of drug therapy and toxicity. The author 
concluded at the time that it was not clear whether the drug therapies used for TMD 
provided any benefit over placebo.  Currently, there have been very few placebo 
controlled trials undertaken to evaluate the efficacy of NSAIDs for the treatment of 
TMD. The aim of this study was to determine whether topical NSAID is more 
effective than placebo for the treatment of temporomandibular pain. 
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Methods 
 
Adult patients attending the Orofacial Pain Clinic at the Centre for Oral Health from 
March 2007 to September 2008 at Westmead Hospital for assessment of facial pain 
were considered possible for involvement in the study. The human research ethics 
committee of Westmead Hospital and The University of Sydney approved the study, 
and all participants gave informed consent.   
As part of a normal assessment in the clinic, each patient completed a pain history 
questionnaire, a psychometric evaluation (Symptom Checklist 90 Revised (SCL-90R) 
- Derogatis 1983) and musculoskeletal examination (Research Diagnostic Criteria for 
Temporomandibular disorders, RDC-TMD6) of the head and neck. The psychometric 
evaluation was not used in this study. After assessment, patients who were diagnosed 
with a localised TMD (myofascial pain with or without arthralgia) where localised 
pain is defined as three or less sites of palpable pain within the masticatory muscles 
and temporomandibular joints, were invited to participate.  
Patients with contraindications to oral NSAID use were excluded. These patients 
include those who have a known or suspected hypersensitivity to diclofenac or other 
NSAIDs, a history of recurrent ulceration, active or recent history of inflammatory 
diseases of the gastrointestinal tract such as peptic ulcers, gastritis, regional ulcer or 
ulcerative colitis. Also, those patients with significant hepatic impairment, active liver 
disease, severely impaired or deteriorating renal function, those who were pregnant or 
those who were receiving treatment for facial pain were also excluded.  
 
At the first appointment; the following outcomes were measured: 
• 11-point numerical rating scale (Turk et al7) between 0 (no pain) and 10 (pain 
as bad as could be) 
• Number of sites that were painful on palpation 
• Pain free jaw mobility (vertical jaw opening with the incisal edges of the 
central incisors used as a reference point measured in millimetres without 
pain) 
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At the end of the first clinic visit, participants were randomly issued with an identical 
container of either topical NSAID-diclofenac 1g/100g (Voltaren Emulgel, Novartis) 
or placebo (sorbolene cream with similar consistency to active drug, Maxi Natural).  
Each container of approximately 110 grams of gel, was weighed and coded with a 3 
digit number.  Both clinical researchers and participants were blinded to the container 
contents. The container codes were kept in a sealed envelope in a locked cabinet and 
not opened until the conclusion of the entire study. Randomisation was achieved by 
computer generated software (Excel Microsoft).  
 
Each subject was instructed to apply the cream over the affected area three times daily 
for a period of two weeks . Specifically, the subjects were instructed to apply a pea-
sized amount of the gel to the skin overlying the painful craniofacial sites.  Each 
subject was provided with written instructions on gel application (Appendix 1) and 
pain assessment measures (Appendix 2) to be completed at home during the two week 
application period. Patients demonstrated the correct application of a non-study gel to 
an experimenter prior to leaving the clinic.  
 
Study pain assessment 
The patients were reviewed following a 2-week period. Each patient completed a pain 
diary for 2 weeks, which consisted of an 11-point numerical rating scale (NRS) for 
facial pain twice daily: 9am and 8pm. In the evening, the patient also rated their level 
of pain relief for the entire day on a five point pain relief categorical scale (0=no pain 
relief, 1=a little pain relief, 2= some pain relief, 3= a lot of pain relief, and 4= 
complete pain relief). At the end of the two week application, the subject was 
reassessed by evaluating the same measures used at the commencement of the study.  
 
Data Analysis 
The primary efficacy end point was determined by the change in pain intensity on the 
11-point numerical rating scale for facial pain between the beginning and the end of 
the study.  
A number of secondary outcomes were also assessed.  
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• The number of days with some pain relief. A two tailed t-test and Mann 
Whitney test was used to determine if the number of pain relief days was 
different between the treatment and placebo groups.  
• The change in pain on palpation and pain free jaw mobility was also 
calculated by subtracting values obtained on day 14 from those obtained on 
day 1 for each patient. A two tailed t-test and Mann Whitney test was be used 
to compare patients who received treatment with those who received placebo. 
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Results  
 
 
Forty eight patients (28 females and 20 males) were recruited. The median age was 42 
years with an age range of 17-72 years. Nine patients discontinued prematurely from 
the study thus leaving a total of thirty nine patients. Four patients did not return to the 
clinic and could not be contacted or refused further treatment. Three patients 
developed gastrointestinal problems and thus did not finish. Two patients developed 
skin irritation to the gel and stopped. The remaining thirty nine patients consisted of 
twenty two placebo and seventeen active trials. The results of this study are shown in 
figures 1-4 illustrated below.   
 
Figure 1 illustrates that the median change of the 11-point NRS in the placebo group 
was 0 whilst the median for change in active group was -1. However, these results did 
not reach levels of significance (p>0.05) as depicted in Table 1 and 2. The results also 
showed that the number of days with some pain relief for both groups was 4 days.  
The change in pain free mobility was greater in placebo group (2.68mm) when 
compared to the active group (2mm). However, utilising a 2-tailed t-test (depicted in 
Table 1), there were no significant differences between the two groups, (p>0.05). 
Finally, the change in the number of sites that were painful was greater in the active 
group when compared to the placebo group but group differences were not significant 
(p>0.05).  
 
 
Fig 1. Change in 11-point pain scale 
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Fig 2. Number of days with some pain relief 
 
Fig 3. Change in pain free mobility (mm)  
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Fig 4. Change in number of painful sites 
 
 
Table 1. t-test of change by treatment 
 
 Treatment N Mean Std. Deviation 
Std. Error 
Mean 
Sig. (2-
tailed) 
Change in NRS Placebo 22 -1.05 1.647 .351 0.928 
  Active 17 -1.00 1.414 .343  
Number of days with 
some pain relief 
Placebo 22 5.77 5.191 1.107 0.945 
  Active 
17 5.88 4.567 1.108 
 
Change in pain free 
mobility (mm) 
Placebo 22 2.68 2.056 .438 0.286 
  Active 17 2.00 1.803 .437  
Change no. sites painful Placebo 22 -.77 3.939 .840 0.431 
  Active 17 -1.65 2.523 .612  
 
Table 2. Mann Whitney Test 
 
 Change in NRS Number of days with some pain 
relief 
Change in pain 
free mobility (mm) 
Change in no. of 
sites painful 
Asymp. Sig. (2-
tailed) 
0.918 0.841 0.267 0.509 
 
Table 3. Distribution of results 
 Treatment 
  Placebo Active 
  Median 
Percentile 
25 
Percentile 
75 Median 
Percentile 
25 
Percentile 
75 
Change in NRS 0 -2 0 -1 -2 0 
Number of days with 
some pain relief 4 0 11 4 3 10 
Change in pain free 
mobility (mm) 3 1 4 2 0 3 
Change no. sites painful -2 -3 4 -2 -3 0 
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Discussion 
 
There are a number of confounding factors present within this study. Firstly, there 
were 6 different operators utilised who assessed the study subjects. Secondly, the 
active and placebo gels have distinctly different scents which may have introduced 
bias into the patients responses.   The limited sample size may not have been 
sufficient to detect a significant difference between the two subject groups.  
Nevertheless, the results of this study are not unlike those of previous studies.  
Minakuchi et al8 studied TMD patients with anterior disc displacement without 
reduction (confirmed by magnetic resonance imaging) and examined the efficacy of 
systemically administered diclofenac (25mg three times daily) versus non-treatment 
(control group). Patients were randomly allocated to one of three groups - control, 
self-care plus NSAIDs, and occlusal appliance plus self-care/NSAIDs. Their results 
showed within group improvements were made for all variables for all groups. 
Between group differences were not highly evident with only mean daily activity 
limitation for the self-care/NSAID group being significantly lower than that of the 
occlusal appliance + self-care/NSAID group at the two and four week time points. A 
confounding factor of this study was that both treatment and control groups exhibited 
a marked improvement in pain during mastication and jaw opening over the study 
period. One difficulty in studying TMD patients is that there appears to be a natural 
fluctuation in pain symptoms which may undergo remission and exacerbation. The 
authors concluded that the gradual reduction in signs and symptoms was non-specific 
and was related not to the type of treatment, but more to the passage of time.  
 
Gordon et al9 reported that Ibuprofen (800mg, three times daily) and Piroxicam 
(20mg daily) were no more efficacious than placebo for the treatment of TMD pain. 
These studies have only been published as an abstract and examined small groups of 
TMD patients (n=30 to 40) who appeared to have mostly joint pain. Nevertheless, this 
suggests that in TMD patients, with predominantly joint-related pain symptoms, 
NSAIDs may not be particularly effective. However, TMD patients with 
predominantly masticatory muscle pain have not been reported.  
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Although considered relatively safe drugs, chronic systemic administration of 
NSAIDs is associated with significant side effects. In particular the development of 
gastrointestinal ulceration, renal dysfunction, and in sensitive individuals, the 
exacerbation of existing hypertension. One approach used to reduce unwanted side 
effects is the use of creams and more recently topical patches or gels containing 
NSAIDs to achieve high concentration near the site of tissue pain, but avoiding 
significant systemic levels.   
 
Di Rienzo et al10 investigated the efficacy of topical versus systemic diclofenac in the 
treatment of TMD. In that study, 36 patients were evenly and randomly allocated to 
two groups. One group received oral diclofenac sodium 50mg tablets twice a day for 
14 days. The second group received 16mg/ml of topical diclofenac sodium and were 
instructed to apply four times daily for a period of 14 days. Patients were asked to 
complete a questionnaire at the beginning and end of treatment. A graded visual 
analogue scale (VAS) and questions pertaining to the pain and tenderness of the 
temporomandibular joint and functional limitation of mouth opening were collected. 
The results indicated that all patients showed relief from pain after treatment. 
However, the difference between the two groups was not significant (p>0.05). Post-
treatment, 16 patients of the first group displayed epigastralgic symptoms. Three 
patients treated with topical diclofenac showed a modest irritation of the 
temporomandibular joint region which disappeared spontaneously. Topical diclofenac 
has the advantage that it does not have adverse systemic effects, whereas oral 
diclofenac had negative effects on the gastrointestinal system. The authors concluded 
that there was little difference between topical and systemic application of non-
steroidal anti-inflammatory drug diclofenac when used for the treatment of TMD.  
 
Ekberg et al11 investigated the effect of a systemically applied NSAID, diclofenac, 
compared with a placebo. In the study, 32 patients with pain localised to the 
temporomandibular joint (TMJ) were evenly allocated to two groups. Only a visual 
analogue scale was used at pre-treatment for baseline data collection. The treatment 
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effect was assessed by the patients’ own evaluation of improvement as well as the 
frequency of joint and muscle pain. The clinical condition was assessed by the degree 
of tenderness to palpation of the TMJ and masticatory muscles and by mandibular 
mobility. The results of this study showed a greater reduction of the frequency of joint 
pain in the group treated with diclofenac as well as a significant reduction of daily 
TMJ pain. This treatment group also showed a significant decrease in tenderness to 
palpation of the masticatory muscles in comparison to the placebo group. The patients 
with short duration of pain showed the best response to diclofenac. It was concluded 
that there was no evidence in the study to prove that diclofenac should be used as a 
primary treatment of TMJ pain, but it could be used as a complement to other 
treatments of acute TMJ pain.  
 
Mason et al12 conducted a systematic review of topical NSAIDs for chronic 
musculoskeletal pain. The number of trials included were 15 placebo controlled, 7 
active controlled and 3 with both active and placebo controls. The total number of 
patients involved were 1502 in placebo controlled trials and 764 in active controlled 
trials. The results showed that in 14 trials with information from 1502 patients, topical 
NSAIDs were significantly better than placebo. Trials included in this review were of 
high quality and validity, so minimising the possibility of bias. However, there was 
insufficient information on different topical NSAID preparations to tell whether one 
was better than another. Another review of topical NSAIDs in musculoskeletal pain 
by Lin et al13 concluded that there was no evidence of superior efficacy beyond two 
weeks of use.  
 
Vaile et al14 published a review of the literature investigating topical NSAIDs for 
musculoskeletal conditions. Human and animal trials indicate that topical NSAIDs 
display lower plasma concentrations when compared with systemic delivery. 
Concentrations of active drug therapy in soft tissues are still of a threshold which is 
considered to have an anti-inflammatory effect. The authors did question the mode of 
delivery of active drug in the joint therapy that is whether the drug reached the joint 
due to transcutaneous or systemic route. Adverse reactions were reported with topical 
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NSAIDs. In approximately 2% of patients there were symptoms ranging from 
gastrointestinal irritation to irritation of the skin. The authors conclude that the 
evidence for the usage of NSAIDs in acute and subacute soft tissue injuries is 
accumulating, however, longer trial periods are necessary.   
 
Ta et al15 compared the efficacy and adverse effects of a celecoxib, a 
cyclogenoxygenase-2 inhibitor, with naproxen (NSAID) and a placebo in the 
treatment of painful TMJs. This study was a randomised double-blind control trial 
with 68 subjects. They were randomly assigned to one of three groups. Group 1 
received celecoxib 100mg twice daily, group 2 received naproxen 500mg twice daily 
and the third group received a placebo for 6 weeks. Primary outcome measurement 
was a change in VAS. The results showed that naproxen significantly reduced the 
symptoms of pain around the joint area. Significant improvements in range of motion 
was observed with naproxen compared to celecoxib and placebo. Celecoxib did show 
better pain reduction than placebo but this was not significant for TMD pain. The 
authors conclude that inhibition of both COX 1 and 2 enzymes are needed to achieve 
effective analgesia for this type of musculoskeletal pain.  
 
Conclusions 
Within the limitations of this study, the results show that the use of NSAIDs for the 
treatment of temporomandibular pain does not give a better result when compared to a 
placebo.  
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Appendix 1 
PARTICIPANT INSTRUCTIONS 
 
Study Title: The effectiveness of a non-steroidal anti-inflammatory drug on jaw pain 
 
 
Chief Investigator: Dr Tuan Dao Department of Oral Restorative Sciences 
 
How to apply the cream to your face 
1. You will be taught how to apply the cream to painful sites on your face at your 
initial appointment. Below is a diagram with the locations where we wish you to apply 
the cream. 
 
2. Place a pea-sized amount of cream (as shown in the clinic) onto your index finger 
and rub it gently into the painful sites of your face three times a day (9am, 2pm, & 
8pm).  
 
3. Do not apply it inside your mouth or in or around your eyes, and remember to 
wash your hands immediately after applying the cream to your face.  
 
4. Remember to record in the diary that you were given your facial pain level twice a 
day; once at 9am and once at 8pm, and also the amount of pain relief your felt for the 
day.   
 
5. Discontinue use and consult the Chief Investigator if a rash or other symptoms 
develop. 
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Appendix 2 
 
 
Complete this at 9 A.M.: 
 
How would you rate your facial pain on a 0 to 10 scale at the present time, that is, right now, 
where 0 is “no pain” and 10 is “pain as bad as could be”? 
 
No 
pain 
        Pain as bad 
as could be 
0 1 2 3 4 5 6 7 8 9 10 
           
 
 
 
 
Complete this at 8 P.M.: 
 
How would you rate your facial pain on a 0 to 10 scale at the present time, that is, right now, 
where 0 is “no pain” and 10 is “pain as bad as could be”? 
 
No 
pain 
        Pain as bad 
as could be 
0 1 2 3 4 5 6 7 8 9 10 
           
 
 
 
 
How would you rate your pain relief for the entire day, where 0 is “no pain relief” and 4 is 
“complete pain relief”? 
 
No pain  
relief 
A little pain 
relief 
Some pain  
relief 
A lot of  
pain relief 
Complete 
pain relief 
0 1 2 3 4 
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